ValuEngine cut shares of OXIS International Inc. (OTCMKTS:OXISD) from a hold rating to a sell rating in a research note released on Friday morning.

OXIS International (OTCMKTS OXISD) traded down 3.23% on Friday, reaching $15.00. 14,557 shares of the company traded hands. The firm’s market cap is $7.44 million. OXIS International has a 52-week low of $3.00 and a 52-week high of $78.70.

WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at

OXIS International Company Profile

GT Biopharma, Inc, formerly OXIS International, Inc, is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates (ADCs), bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic (ADDCs) agents.

Receive News & Ratings for OXIS International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OXIS International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.